大便失禁(Fecal Incontinence):治療薬開発パイプライン動向2015

◆英語タイトル:Fecal Incontinence-Pipeline Insights, 2015
◆商品コード:DELVP501245
◆発行会社(調査会社):DelveInsight
◆発行日:2015年版(※最新版はお問い合わせください)
◆ページ数:60以上
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(納品まで約3営業日)
◆調査対象地域:グローバル
◆産業分野:製薬
◆販売価格オプション(消費税別)
Single User(1名使用)USD1,250 ⇒換算¥138,750見積依頼/購入/質問フォーム
Site Price(同一国内共有可)USD2,500 ⇒換算¥277,500見積依頼/購入/質問フォーム
Enterprise Price(複数国内共有可)USD4,000 ⇒換算¥444,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご確認ください。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(支払期限と方法は調整可能、振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はDelveInsight社の日本における正規販売代理店です。DelveInsight社の概要及び新刊レポートはこちらでご確認いただけます。
本調査レポートでは、世界における大便失禁(Fecal Incontinence)の治療薬開発パイプライン動向について調査・分析し、企業別開発中の治療薬、各臨床試験段階における製品リスト及び比較分析、薬剤候補のプロファイル、治療薬の評価、開発中止又は開発休止中の製品リスト等をお届けしています。また、大便失禁(Fecal Incontinence)治療薬開発に取り組んでいる企業情報も提供しています。(※本レポートはご注文を頂いてから、最新データに更新して納品しているため、正確なページ数を明記しておりません。)

・大便失禁(Fecal Incontinence)の概要

・大便失禁(Fecal Incontinence)のパイプライン製品概要

・企業別開発中の治療薬

・後期治験段階の製品(Filed & Phase III):比較分析

・中期治験段階の製品(Phase II):比較分析

・初期治験段階の製品(Phase I & IND):比較分析

・前臨床段階の製品:比較分析

・薬剤候補のプロファイル

・大便失禁(Fecal Incontinence)治療薬の評価
  - 単剤治療薬
  - 併用治療薬
  - 投与経路別
  - 分子の種類別

・開発が中止された製品リスト

・開発休止中の製品リスト

・大便失禁(Fecal Incontinence)治療薬開発に取り組んでいる企業リスト

・図表一覧
【レポートの概要】

SUMMARY
DelveInsight’s,“ Fecal Incontinence-Pipeline Insights, 2015”, report provides comprehensive insights about pipeline drugs across this indication. A key objective of the report is to establish the understanding for all the pipeline drugs that fall under Fecal Incontinence. This report provides information on the therapeutic development based on the Fecal Incontinence dealing with all the pipeline drugs, comparative analysis at various stages covering Filed, Phase III, Phase II, Phase I, IND filed, Preclinical, Discovery and unknown stages, therapeutics assessment by monotherapy and combination products and molecule type drug information. The report also covers the companies information involved in the therapeutic development of the products. It also has highlighted the discontinued and dormant products.

[Data Sources]

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by DelveInsight team of industry experts.

Secondary sources information and data has been collected from various printable and non-printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Magazines, Trade associations, Books, Industry Portals, Industry Associations and access to available databases.

Note*: This report requires certain updates. We have all the information available but require 3 business days to complete the process and ensure it is as up-to-date as possible. Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated Indication.


Scope
• The report provides a snapshot of the global therapeutic landscape of Fecal Incontinence
• The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
• Coverage of the Fecal Incontinence pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
• The report reviews key players involved in the therapeutics development for Fecal Incontinence and also provide company profiling
• The report also gives the information of dormant and discontinued pipeline projects
• Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages
• Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type


【レポートの目次】

Table of Contents
• Fecal Incontinence Overview
• Fecal Incontinence Pipeline Therapeutics
• Fecal Incontinence Therapeutics under Development by Companies
• Fecal Incontinence Late Stage Products (Filed and Phase III)
– Comparative Analysis
• Fecal Incontinence Mid Clinical Stage Products (Phase II)
– Comparative Analysis
• Fecal Incontinence Early Clinical Stage Products (Phase I and IND Filed)
– Comparative Analysis
• Fecal Incontinence Discovery and Pre-Clinical Stage Products
– Comparative Analysis
• Drug Candidate Profiles
• Fecal Incontinence – Therapeutics Assessment
– Assessment by Monotherapy Products
– Assessment by Combination Products
– Assessment by Route of Administration
– Assessment by Molecule Type
• Fecal Incontinence – Discontinued Products
• Fecal Incontinence – Dormant Products
• Companies Involved in Therapeutics Development for Fecal Incontinence
• Appendix
• Methodology
• Contact Us
• Disclaimer

List of Tables
• Number of Products under Development for Fecal Incontinence, 2015
• Number of Products under Development by Companies
• Comparative Analysis by Late Clinical Stage Products (Filed and Phase III), 2015
• Comparative Analysis Mid Clinical Stage Products (Phase II), 2015
• Comparative Analysis Early Clinical Stage Products (Phase I and IND Filed), 2015
• Comparative Analysis Discovery and Pre-Clinical Stage Products, 2015
• Drug Candidates Profiles
• Fecal Incontinence Assessment by Monotherapy Products
• Fecal Incontinence Assessment by Combination Products
• Fecal Incontinence Assessment by Route of Administration
• Fecal Incontinence Assessment by Stage and Route of Administration
• Fecal Incontinence Assessment by Molecule Type
• Fecal Incontinence Assessment by Stage and Molecule Type
• Fecal Incontinence Therapeutics – Discontinued Products
• Fecal Incontinence Therapeutics – Dormant Products
• Products under Development by Companies, 2015


List of Figures
• Number of Products under Development for Fecal Incontinence, 2015
• Late Clinical Stage Products (Filed and Phase III), 2015
• Mid Clinical Stage Products (Phase II), 2015
• Early Clinical Stage Products (Phase I and IND Filed), 2015
• Discovery and Pre-Clinical Stage Products, 2015
• Fecal Incontinence Assessment by Monotherapy Products
• Fecal Incontinence Assessment by Combination Products
• Fecal Incontinence Assessment by Route of Administration
• Fecal Incontinence Assessment by Stage and Route of Administration
• Fecal Incontinence Assessment by Molecule Type
• Fecal Incontinence Assessment by Stage and Molecule Type


【レポートのキーワード】

大便失禁(Fecal Incontinence)、治療薬(医薬品、薬剤)、製薬企業、研究開発、治験、製品パイプライン

★調査レポート[大便失禁(Fecal Incontinence):治療薬開発パイプライン動向2015] (コード:DELVP501245)販売に関する免責事項を必ずご確認ください。
★調査レポート[大便失禁(Fecal Incontinence):治療薬開発パイプライン動向2015]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆